Abstract library

549 results for "gastrointestinal stromal tumour".
#2911 Pancreatic Neuroendocrine Neoplasms and GastroIntestinal Stromal Tumours: A Single-Institution Experience of a Rare Association and Review of the Literature
Introduction: Pancreatic neuroendocrine neoplasms (pNENs) and gastrointestinal stromal tumours (GISTs) are both rare neoplasms, and they have an estimated incidence of about 1/100,000 per year and about 1-1.5/100,000 per year, respectively.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W, ...
#2999 Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
Introduction: Increased levels of serotonin secretion are associated with mesenteric fibrosis (MF) in small intestinal neuroendocrine tumors (SI-NETs). However, only a proportion of patients with increased serotonin production will develop mesenteric fibrosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs. Anela Blazevic
#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels
Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Philippe Ruszniewski
#2919 Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs
Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: A/Prof Nick Pavlakis
#349 Gastrointestinal Stromal Tumor (GIST) Of The Esophagus In A Patient With MEN-1 And-Related Pancreatic Gastrinoma
Introduction: Both Multiple Endocrine Neoplasia type 1 (MEN-1; OMIM #613733)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs; OMIM #606764) are rare neoplasms and their association has been rarely reported so far.
Conference:
Category: Basic
Presenting Author: Dr Roberta E Rossi
#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs Kris Samsom
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement